- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03121079
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
September 21, 2020 updated by: Xiaojun Huang,MD, Peking University People's Hospital
Interferon-α Prevents Leukemia Relapse of AML Patients Undergoing HLA-identical Allogeneic Hematopoietic Stem Cell Transplantation With Pretransplant MRD
Allogeneic stem cell transplantation (SCT) remains a powerful therapeutic modality for patients with acute myeloid leukemia (AML).The superior clinical outcomes of allogeneic human SCT versus chemotherapy alone as post-remission treatment could be related to the graft-versus-leukemia (GVL) effects of recovered donor T cells.
Our previous study investigated both the association of MRD status with transplant outcomes in haplo-SCT and matched sibling donor transplantation(MSDT), and also possible differences in the transplant outcomes of patients with positive pre-MRD (as determined by MFC) who underwent haplo-SCT versus MSDT.
It provided new evidence that unmanipulated haplo-SCT is superior to matched sibling donor transplantation in eradicating pre-transplantation MRD, indicating that unmanipulated haploidentical allografts have stronger GVL effects.As to the AML patients in standard-risk, who have a positive MRD before MSDT, whether these patients should be given any relapse prevention is the question to be answered in this study.
Interferon α-2b exerts a relatively strong immunomodulatory effect.
It can kill AL cells by regulating T-cell and/or natural killer cell functions.Consequently, interferon α-2b may have potential value for high-risk AL patients after transplantation.
The study hypothesis: Using interferon α-2b following hematopoietic stem cell transplantation in patients with standard-risk AML can further reduce relapse rate and improve leukemia-free survival.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
The standard-risk AML patients (18-60 years) receiving HLA-identical allogeneic stem cell transplantation in Peking University Institute of Hematology will be enrolled in this study if their MRD were positive before SCT, in CR1/CR2, remain in CR and MRD negative in the first two months after transplantation.
The patients in this study will be treated with interferon-alpha injection twice a week (3 million units / time, iH) since the third month posttransplant.
If the patients were well tolerated, the interferon-alpha treatment will continue 6 months.
All the enrolled patients will undergo MRD monitoring after SCT as the same as the routine procedure.
Bone marrow examination will be performed at the regular time points (+1, 2,3, 4, 5, 6, 9, 12 month) and 8-colour flow cytometry and RQ-PCR-based WT1 examination will be empolyed to evaluate MRD and disease status.
Based on the statistical calculation, in order to reduce the incidence of relapse from 40% (previous data) to 15% (the cumulative incidence of relapse in pre-MRD- AML patients), total 29 patients will be enrolled.
The main side effects might related to interferon-alpha include induction of severe GVHD, hematological toxicity and Flu - like symptoms.
If the patients met the following criteria, they will withdraw from the trial: 1)met the combined criteria for positive MRD (MRDco+) which was defined as 2 consecutive FCM+ or WT1+ results or both FCM+ and WT1+ in a single sample within 1 year after transplantation; 2)hematological relapse; 3) grade III or IV acute GVHD, or moderate/ severe chronic GVHD; 4) severe infection; 5) grade IV hematological toxicity; 6) organ failure; 7) death; 8) patients refuse to continue the interferon-alpha treatment.
The main end point of the study is one-year cumulative incidence of relapse.
the second end points include OS, NRM, DFS, MRD, GVHD, infection and hematological toxicity.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100044
- Peking University People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- standard-risk AML in CR1/CR2
- without t(9;22) and t(15;17)
- receive HLA-identical transplantation
- with positive MRD before transplantation (measured by flow cytometry)
- CR within the first two months posttransplantation and MRD is negative
- between 18-60 years
Exclusion Criteria:
- uncontrolled GVHD
- be in myelosuppression (WBC<1.5x10^9/L, ANC<0.5×10^9/L,PLT<25×10^9/L,HB<65g/L)
- severe infection
- organ failure
- the patients do not agree to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interferon alpha group
The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
|
patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cumulative incidence of relapse
Time Frame: within the first year after transplantation
|
the cumulative incidence of relapse
|
within the first year after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: within the first year after transplantation
|
overall survival
|
within the first year after transplantation
|
NRM
Time Frame: within the first year after transplantation
|
non-relapse motality
|
within the first year after transplantation
|
DFS
Time Frame: within the first year after transplantation
|
disease-free survival
|
within the first year after transplantation
|
MRD
Time Frame: within the first year after transplantation
|
cumulative incidence of MRD+
|
within the first year after transplantation
|
acute GVHD
Time Frame: within 100 days after transplantation
|
acute graft-versus-host disease
|
within 100 days after transplantation
|
chronic GVHD
Time Frame: within the first year after transplantation
|
chronic graft-versus-host disease
|
within the first year after transplantation
|
infection
Time Frame: within the first year after transplantation
|
bacteria, fungal, virus, etc.
|
within the first year after transplantation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematologic toxicity
Time Frame: within the first year after transplantation
|
any decrease of blood cells including white, red blood cells and platelet
|
within the first year after transplantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiaojun Huang, Dr., Peking University Institute of Hematology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2017
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
April 14, 2017
First Submitted That Met QC Criteria
April 14, 2017
First Posted (Actual)
April 19, 2017
Study Record Updates
Last Update Posted (Actual)
September 23, 2020
Last Update Submitted That Met QC Criteria
September 21, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017PHB013-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapse
-
Centre Hospitalier Henri LaboritRecruiting
-
Cairo UniversityNot yet recruiting
-
Poliklinika OrthonovaUniversity of Zagreb School of Dental Medicine, Zagreb, Croatia; University...RecruitingOrthodontic RelapseCroatia
-
Sydney Local Health DistrictRecruiting
-
University of MinnesotaNational Institute on Drug Abuse (NIDA)Recruiting
-
Care Team SolutionsCompleted
-
Yale UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedPostpartum Smoking RelapseUnited States
-
Semra YILMAZCompletedPostpartum Smoking RelapseTurkey
-
University of DelawareDelaware Department of Probation & ParoleUnknownRecidivism | Probationary Failure | Drug RelapseUnited States
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Nabi...CompletedSmoking Behavior | Smoking Lapse Behavior | Smoking Relapse BehaviorNetherlands
Clinical Trials on Interferon-alpha
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.CytoPharm, Inc.Completed
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
University Hospital TuebingenDermatologic Cooperative Oncology GroupCompleted
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedMalignant Pleural MesotheliomaUnited States
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.Texas Tech University Health Sciences CenterTerminatedPulmonary Disease, Chronic Obstructive | Cough | Pulmonary FibrosisUnited States
-
French Innovative Leukemia OrganisationCompletedLeukemia, Lymphocytic, AcuteFrance
-
National Cancer Institute, MilanAssociazione Italiana per la Ricerca sul CancroCompletedLiver Cirrhosis | Hepatocellular Carcinoma | Hepatitis C Virus Infection | Hepatic Resection | Interferon TreatmentItaly
-
Azidus BrasilCompleted
-
Spanish Oncology Genito-Urinary GroupGlaxoSmithKlineCompletedAdvanced Renal Cell CarcinomaSpain